This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Sandbox PgpWWC
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
==P-glycoprotein (ABCB1)== | ==P-glycoprotein (ABCB1)== | ||
<StructureSection load='4q9h' size='340' side='right' caption='ABCB1: 3.4 Å resolution 'scene=''> | <StructureSection load='4q9h' size='340' side='right' caption='ABCB1: 3.4 Å resolution 'scene=''> | ||
| - | '''P-glycoprotein (P-gp, ABCB1)''' is an ATP binding casette transporter that hydrolyses ATP for conformational changes after a variety of substrates are transported. It is one of the membrane proteins responsible for the multi drug resistance (MDR) in cancer treatment, as well as various other drug therapies.<ref | + | '''P-glycoprotein (P-gp, ABCB1)''' is an ATP binding casette transporter that hydrolyses ATP for conformational changes after a variety of substrates are transported. It is one of the membrane proteins responsible for the multi drug resistance (MDR) in cancer treatment, as well as various other drug therapies.<ref name="Aller"/>PMID: 19325113</ref><ref>He, L., & Liu, G. Q. (2002). Effects of various principles from Chinese herbal medicine on rhodamine123 accumulation in brain capillary endothelial cells. Acta Pharmacologica Sinica, 23(7), 591-596</ref> ABCB1 can be found in tumor cells, as well as in the liver, kidney, adrenal gland, intestine, blood-brain barrier (BBB), placenta, blood-testis barrier, and blood-ovarian barriers. An effective MDR transport protein, the high amount of active ABCB1 substrates stems from the polyspecificity for hydrophobic and aromatic compounds.<ref>Marchetti, S., Mazzanti, R., Beijnen, J. H., & Schellens, J. H. (2007). Concise review: clinical relevance of drug–drug and herb–drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). The Oncologist, 12(8), 927-941.</ref> |
{{Template:ColorKey_Hydrophobic}}, {{Template:ColorKey_Polar}} | {{Template:ColorKey_Hydrophobic}}, {{Template:ColorKey_Polar}} | ||
<scene name='69/699852/Hydrophobic_residues/4'>Here</scene> | <scene name='69/699852/Hydrophobic_residues/4'>Here</scene> | ||
Revision as of 20:27, 23 April 2015
P-glycoprotein (ABCB1)
| |||||||||||
References
- ↑ Cite error: Invalid
<ref>tag; no text was provided for refs namedAller - ↑ He, L., & Liu, G. Q. (2002). Effects of various principles from Chinese herbal medicine on rhodamine123 accumulation in brain capillary endothelial cells. Acta Pharmacologica Sinica, 23(7), 591-596
- ↑ Marchetti, S., Mazzanti, R., Beijnen, J. H., & Schellens, J. H. (2007). Concise review: clinical relevance of drug–drug and herb–drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). The Oncologist, 12(8), 927-941.
- ↑ Aller, S., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., . . . Chang, G. (2009). Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding. Science, 323(5922), 1718-1722.
- ↑ Chufan, E. E., Sim, H. M., & Ambudkar, S. V. (2014). Chapter Three – Molecular Basis of the Polyspecificity of P-Glycoprotein (ABCB1): Recent Biochemical and Structural Studies. Advances in Cancer Research, 125, 71-96
- ↑ Aller, S., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., . . . Chang, G. (2009). Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding. Science, 323(5922), 1718-1722.
